CRISPLD2, a novel insulin‐sensitizing adipokine that alters adipocyte size
Obesity · 2025
DOI: 10.1002/oby.24342 ↗At a glance
Journal article in Obesity, 2025. Written by Beth A Griesel and 5 co-authors. Institution: Department of Biochemistry and Physiology, University of Oklahoma Health Sciences, Oklahoma City, Oklahoma, USA. Major MEDLINE topics: Adipocytes, Insulin Resistance, Obesity, Cell Adhesion Molecules. Cited 1 times so far (Crossref); 25 references. The full text is freely available in PubMed Central. Funded by: NIA NIH HHS, NIH HHS, Oklahoma Center for the Advancement of Science and Technology.
Abstract (original language)
Objective
Both obesity and adipose tissue fibrosis are associated with insulin resistance, which can improve with weight loss. We previously found increased adipocyte‐specific secretion of the novel adipokine CRISPLD2 during weight loss. In this study, we further explore the function of adipose CRISPLD2, which others suggest may regulate inflammation and fibrosis in a variety of tissues.
Methods
We designed mice with adipose‐specific doxycycline‐inducible overexpression of CRISPLD2 (CLD2 AD ) to assess adipose‐specific effects on tissue structure and function on chow or high‐fat diets. The effects of prolonged excess CRISPLD2 were determined after 7 months, including stromal vascular fraction analysis by single‐cell RNA‐seq. CRISPLD2 cell surface signaling was explored in 3T3‐L1 adipocytes via transwell assays, and adipocyte binding partners were determined in unbiased binding screening by mass spectrometry.
Results
CLD2 AD mice had decreased adipocyte size but unchanged fat mass. Long‐term CRISPLD2 overexpression led to downregulation of collagen transcription and decreased fibrosis. CRISPLD2 induced Ifng transcription in adipocytes in vitro and bound multiple adipocyte cell surface proteins, including nucleolin. Finally, obese CLD2 AD mice had decreased adipocyte size and improved glucose tolerance, with no change in fat mass.
Conclusions
These data suggest a model wherein CRISPLD2 can both regulate adipose tissue fibrosis and improve insulin sensitivity.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Biochemistry and Physiology, University of Oklahoma Health Sciences, Oklahoma City, Oklahoma, USA.
- Oklahoma Center for Geroscience and Healthy Brain Aging, University of Oklahoma Health Sciences, Oklahoma City, Oklahoma, USA.
- Department of Chemistry and Biochemistry, Mass Spectrometry, Proteomics and Metabolomics Core Facility, Stephenson Life Sciences Research Center, University of Oklahoma, Norman, Oklahoma, USA.
- Touchstone Diabetes Center, The University of Texas Southwestern Medical Center, Dallas, Texas, USA.
- Department of Pediatrics, University of Oklahoma Health Sciences, Oklahoma City, Oklahoma, USA.
ORCID profiles: Philipp E Scherer, Ann Louise Olson, David P Sparling
Funding
- NIA NIH HHS
- NIH HHS
- Oklahoma Center for the Advancement of Science and Technology
- NIDDK NIH HHS
- NIGMS NIH HHS
- National Institutes of Health
Cite
APA
Griesel, B. A., Williams, K., Ahsan, N., Scherer, P. E., Olson, A. L., & Sparling, D. P. (2025). CRISPLD2, a novel insulin‐sensitizing adipokine that alters adipocyte size. Obesity. https://doi.org/10.1002/oby.24342
Vancouver
Griesel BA, Williams K, Ahsan N, Scherer PE, Olson AL, Sparling DP. CRISPLD2, a novel insulin‐sensitizing adipokine that alters adipocyte size. Obesity. 2025. doi:10.1002/oby.24342
BibTeX
@article{Griesel2025,
author = {Griesel, Beth A and Williams, Kylie and Ahsan, Nagib and Scherer, Philipp E and Olson, Ann Louise and Sparling, David P},
title = {CRISPLD2, a novel insulin‐sensitizing adipokine that alters adipocyte size},
journal = {Obesity},
year = {2025},
doi = {10.1002/oby.24342}
}
EUVIMED